MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-21-2026
XTL Biopharmaceuticals Ltd. Total Shareholders Equity 2011-2026 | XTLB
Annual Total Shareholders Equity XTL Biopharmaceuticals Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 3.61 M | 6.52 M | 7.27 M | 3.62 M | 2.69 M | 4.89 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.27 M | 2.69 M | 4.77 M |
Quarterly Total Shareholders Equity XTL Biopharmaceuticals Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 5.33 M | - | 3.28 M | 4.37 M | 3.61 M | - | 5.6 M | 6.71 M | 6.52 M | - | - | - | 7.27 M | - | - | - | 3.62 M | - | - | - | 2.69 M | - | - | - | 4.89 M | - | - | - | 4.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.27 M | 2.69 M | 4.88 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
6.72 B | $ 7.72 | 1.85 % | $ 6.83 B |  Spain |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 19.68 | 0.92 % | $ 920 M |  USA |
 |
Amarin Corporation plc
AMRN
|
459 M | $ 14.5 | 0.03 % | $ 6.02 B |  Irlanda |
 |
GlaxoSmithKline plc
GSK
|
20.8 B | $ 52.37 | 1.02 % | $ 173 B |  Britain |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 221.59 | -0.13 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
Autolus Therapeutics plc
AUTL
|
427 M | $ 1.39 | 1.46 % | $ 355 M | Britain |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M |  Canada |
 |
Heron Therapeutics
HRTX
|
14.3 M | $ 0.81 | 3.74 % | $ 135 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M |  Israel |
 |
Benitec Biopharma
BNTC
|
97.3 M | $ 11.05 | 0.64 % | $ 455 M | USA |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
8.38 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | USA |
 |
Immunovant
IMVT
|
707 M | $ 24.1 | 4.85 % | $ 3.65 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | USA |
 |
Incyte Corporation
INCY
|
5.17 B | $ 90.36 | -0.47 % | $ 17.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
12.1 M | $ 0.74 | -9.75 % | $ 1.81 M | Canada |
 |
INmune Bio
INMB
|
37.3 M | $ 1.17 | -0.43 % | $ 21 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
103 M | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
Innate Pharma S.A.
IPHA
|
156 M | $ 1.35 | 15.38 % | $ 235 M | France |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
106 M | $ 4.43 | 4.6 % | $ 735 M | Canada |
 |
Inventiva S.A.
IVA
|
111 M | $ 6.1 | 5.5 % | $ 138 M | France |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |